Lantheus Holdings, Inc (LNTH) is a publicly traded Healthcare sector company. As of May 21, 2026, LNTH trades at $95.47 with a market cap of $6.06B and a P/E ratio of 22.77. LNTH moved +3.52% today. Year to date, LNTH is +39.30%; over the trailing twelve months it is +25.07%. Its 52-week range spans $47.25 to $118.21. Analyst consensus is strong buy with an average price target of $103.25. Rallies surfaces LNTH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lantheus jumps after Q1 2026 results and reaffirmed 2026 guidance: Lantheus reported first-quarter 2026 results and reaffirmed full-year 2026 guidance. The update also highlighted FDA approval of PYLARIFY TruVu with a phased launch planned for Q4 2026.
| Metric | Value |
|---|---|
| Price | $95.47 |
| Market Cap | $6.06B |
| P/E Ratio | 22.77 |
| EPS | $4.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $118.21 |
| 52-Week Low | $47.25 |
| Volume | 607.36K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.55B |
| Net Income | $279.03M |
| Gross Margin | 60.48% |
9 analysts cover LNTH: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $103.25.